Amgevita, Amgen’s Humira biosimilar, is being rolled out in markets across Europe this week.
The treatment is the first Humira biosimilar to be approved by the European Commission and the first inflammation biosimilar from Amgen’s portfolio to launch in Europe.
Amgevita is authorised for treating of inflammatory diseases in adults, including moderate-to-severe rheumatoid arthritis; psoriatic arthritis; moderate-to-severe Crohn’s disease and moderate-to-severe ulcerative colitis, among others.
It is also authorised for the treatment of paediatric inflammatory diseases, including moderate-to-severe Crohn’s disease (ages six and older), severe chronic plaque psoriasis (ages four and older), enthesitis-related arthritis (ages six and older) and polyarticular juvenile idiopathic arthritis (ages two and older).
“The launch of Amgevita in Europe is an important milestone for our biosimilars portfolio, expanding the range of treatment options for the millions of patients living with chronic inflammatory diseases,” said David M. Reese, Executive Vice President of R&D at Amgen.
” Amgevita is Amgen’s second biosimilar to launch in Europe, demonstrating our commitment to providing patients with serious illnesses access to high-quality biological therapies.”